What is described is a pharmaceutical formulation for intranasal delivery of glucagon-like protein-1 (GLP-1), comprising an aqueous mixture of GLP-1, a solubilizing agent, a chelator, and a surface active agent.

 
Web www.patentalert.com

< Treatment of gestational diabetes

< Methods of diagnosing & treating diabetes and insulin resistance

> Therapeutic agents and methods for cardiovascular disease

> Methods and compositions for treatment of central and peripheral nervous system disorders and novel compounds useful therefor
~ 00251